These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 35193933)
1. ISA101 and nivolumab for HPV-16 Sousa LG; Rajapakshe K; Rodriguez Canales J; Chin RL; Feng L; Wang Q; Barrese TZ; Massarelli E; William W; Johnson FM; Ferrarotto R; Wistuba I; Coarfa C; Lee J; Wang J; Melief CJM; Curran MA; Glisson BS J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193933 [TBL] [Abstract][Full Text] [Related]
2. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. Massarelli E; William W; Johnson F; Kies M; Ferrarotto R; Guo M; Feng L; Lee JJ; Tran H; Kim YU; Haymaker C; Bernatchez C; Curran M; Zecchini Barrese T; Rodriguez Canales J; Wistuba I; Li L; Wang J; van der Burg SH; Melief CJ; Glisson B JAMA Oncol; 2019 Jan; 5(1):67-73. PubMed ID: 30267032 [TBL] [Abstract][Full Text] [Related]
3. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835 [TBL] [Abstract][Full Text] [Related]
4. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S Front Immunol; 2018; 9():1769. PubMed ID: 30108590 [TBL] [Abstract][Full Text] [Related]
5. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497 [TBL] [Abstract][Full Text] [Related]
6. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413 [TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365 [TBL] [Abstract][Full Text] [Related]
10. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect. Lee J; Kim B; Jung HA; La Choi Y; Sun JM Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755 [TBL] [Abstract][Full Text] [Related]
12. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834 [TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498 [TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. Lorentzen CL; Kjeldsen JW; Ehrnrooth E; Andersen MH; Marie Svane I J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217243 [TBL] [Abstract][Full Text] [Related]
16. Tumor mutational load, CD8 Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958 [TBL] [Abstract][Full Text] [Related]
17. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789 [TBL] [Abstract][Full Text] [Related]
18. Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. Niemeijer AN; Sahba S; Smit EF; Lissenberg-Witte BI; de Langen AJ; Thunnissen E Br J Cancer; 2020 Aug; 123(3):392-402. PubMed ID: 32433601 [TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]